Medtronic announced regulatory milestones for software used with two cardiac ablation platforms. This includes FDA clearance and CE Mark for the latest Affera Prism-2 Mapping Software. The company… read more.
Bristol Myers Squibb announced that the FDA approved CAMZYOS (mavacamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms in adults and… read more.
Eli Lilly and Company announced results from a new analysis showing that Foundayo (orforglipron) 17.2 mg was associated with significantly greater weight loss and better blood sugar control… read more.
Emergency Medicine & Intensive Care
The risk of death for patients treated in the emergency department increases by one per cent for every ten per cent increase in occupancy, according to research that… read more.
Various studies over the years have linked prenatal use of the pain reliever paracetamol (acetaminophen) with neurodevelopmental disorders such as autism and attention-deficit/hyperactivity disorder (ADHD) in children, but… read more.
Phathom Pharmaceuticals, Inc. announced the initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 study evaluating an as-needed (PRN or on-demand) investigational dosing regimen of Voquezna (vonoprazan)… read more.
Researchers from Oxford Population Health analysed clinic blood pressure measurements collected by Our Future Health, the UK’s largest health research programme, from participants who enrolled between 2022 and… read more.
Merck, known as MSD outside of the United States and Canada, and Eisai announced the FDA has approved the dual oral regimen of WELIREG (belzutifan), Merck’s first-in-class oral… read more.
Eli Lilly and Company announced that the FDA approved Olumiant (baricitinib), a once-daily pill, for the treatment of pediatric patients 12 years of age and older with severe… read more.
Eli Lilly and Company announced the FDA approval of Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin, indicated along with diet and exercise to control high blood sugar in adults… read more.
Eli Lilly and Company announced results from a new analysis showing that Zepbound (tirzepatide) 10 mg and 15 mg, a dual GIP and GLP-1 receptor agonist, delivered greater… read more.
Pharming announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) seeking approval for lower doses of Joenja (leniolisib), an oral,… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
